AzurRx BioPharma (AZRX) Reports First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in CF Patients

Go back to AzurRx BioPharma (AZRX) Reports First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in CF Patients
(NASDAQ: AZRX) Delayed: 0.72 -0.01 (1.37%)
Previous Close $0.73    52 Week High $5.60 
Open $0.80    52 Week Low $3.98 
Day High $0.80    P/E N/A 
Day Low $0.70    EPS $0.00 
Volume 2,736,000